244 related articles for article (PubMed ID: 34654641)
1. Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era.
Ishii A; Jo T; Arai Y; Oshima S; Kanda J; Kitawaki T; Matsui K; Niwa N; Nakagawa Y; Takaori-Kondo A; Nagao M
Cytotherapy; 2022 Jan; 24(1):49-58. PubMed ID: 34654641
[TBL] [Abstract][Full Text] [Related]
2. Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts.
Holmberg LA; Linenberger M; Connelly-Smith L
Transplant Cell Ther; 2022 Nov; 28(11):754-759. PubMed ID: 36002104
[TBL] [Abstract][Full Text] [Related]
3. Autologous peripheral blood stem cell mobilization and collection in patients with lymphoma and multiple myeloma: A single-center experience using the plerixa for pre-emptive approach.
Alsaeed AS; Najib MJ; Al Amoudi SM; Elhemaidi IY; Absi AA; Al Ahmadi MD; Eldadah SK; Rajkhan WA; Khalil MM; Almohammadi MH
Saudi Med J; 2022 Jun; 43(6):626-632. PubMed ID: 35675941
[TBL] [Abstract][Full Text] [Related]
4. Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/-plerixafor.
Yang C; Dehghani M; Hopman W; Bhella S
J Clin Apher; 2022 Aug; 37(4):348-353. PubMed ID: 35218068
[TBL] [Abstract][Full Text] [Related]
5. Third time's a charm? Mobilization of autologous peripheral blood stem cells in patients with two previous failed mobilizations with plerixafor.
Zhuang L; Boriboonnangkul P; Wang S; Yuan S
Transfusion; 2020 Jun; 60(6):1253-1259. PubMed ID: 32483875
[TBL] [Abstract][Full Text] [Related]
6. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
7. Impact of Plerixafor Use at Different Peripheral Blood CD34
Shah EE; Young RP; Wong SW; Damon LE; Wolf JL; Shah ND; Leavitt AD; Loeffler P; Martin TG
Biol Blood Marrow Transplant; 2020 May; 26(5):876-883. PubMed ID: 31785375
[TBL] [Abstract][Full Text] [Related]
8. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
Lee KH; Jung SK; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW; Kim DW; Kang ES
Vox Sang; 2014 Nov; 107(4):407-15. PubMed ID: 25130876
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: A single-center experience.
He X; Jiang D; Zhao L; Chen S; Zhu Y; He Q; He Y
Cancer Med; 2024 Jun; 13(11):e7356. PubMed ID: 38850125
[TBL] [Abstract][Full Text] [Related]
10. Plerixafor strategies for autologous hematopoietic cell transplant mobilization: A comparison of efficacy and cost.
Chen KY; Bucci TG; Shaw JR; Alexander MD; Grgic T; Riches M; Ptachcinski JR
Transfus Apher Sci; 2022 Apr; 61(2):103303. PubMed ID: 34801430
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of plerixafor in autologous peripheral blood stem cell collection].
Yogo T; Tsukada N; Nashimoto J; Uto Y; Sato K; Miyazaki K; Ogura M; Yoshiki Y; Abe Y; Okazuka K; Ishida T; Suzuki K
Rinsho Ketsueki; 2019; 60(3):165-170. PubMed ID: 31068511
[TBL] [Abstract][Full Text] [Related]
12. Impact of CD34+ pre-counting and plerixafor on autologous peripheral blood stem cell collection in Japanese university hospitals in eight years.
Nakamura Y; Okubo M; Furuta Y; Tokida M; Ichikawa K; Ohsaka A
Transfus Apher Sci; 2019 Dec; 58(6):102664. PubMed ID: 31753774
[TBL] [Abstract][Full Text] [Related]
13. Addition of plerixafor in poorly mobilized allogeneic stem cell donors.
Zhuang L; Lauro D; Wang S; Yuan S
J Clin Apher; 2022 Aug; 37(4):388-394. PubMed ID: 35633513
[TBL] [Abstract][Full Text] [Related]
14. A comparison of four leukapheresis methods to harvest an optimal dose of CD34+ cells: A single center experience.
Lin Y; Park Y; Khanal A; Campbell-Lee S; Liu L; Chen Z; Patel P; Vidanovic V; Sweiss K; Irene G; Peace D; Rondelli D; Mahmud N
Eur J Haematol; 2022 Dec; 109(6):711-718. PubMed ID: 36030395
[TBL] [Abstract][Full Text] [Related]
15. Threshold for optimal administration of plerixafor in autologous peripheral blood stem cell collections through CD34+ cell monitoring based on the experience from two Japanese university hospitals.
Okubo M; Furuta Y; Nakamura Y; Osawa T; Tada N; Sawada T; Yamatoya K; Sekiguchi Y; Araki Y; Miyake K; Noguchi M; Komatsu N; Ohsaka A
Ther Apher Dial; 2021 Oct; 25(5):687-696. PubMed ID: 33325621
[TBL] [Abstract][Full Text] [Related]
16. [A Single-Center Analysis of the Use of G-CSF Combined with Plerixafor to Mobilize Peripheral Blood Hematopoietic Stem Cell from Healthy Related Donors in Allogeneic Hematopoietic Stem Cell Transplantation].
Chen J; Yuan LL; Zhang X; Qiao JL; Yin QX; Zhang YM; Yang XL; Cao XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):286-291. PubMed ID: 35123641
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.
Micallef IN; Sinha S; Gastineau DA; Wolf R; Inwards DJ; Gertz MA; Hayman SR; Hogan WJ; Johnston PB; Lacy MQ; Ansell SM; Buadi F; Dingli D; Dispenzieri A; Litzow MR; Porrata LF; Winters JL; Kumar S
Biol Blood Marrow Transplant; 2013 Jan; 19(1):87-93. PubMed ID: 22922211
[TBL] [Abstract][Full Text] [Related]
18. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
[TBL] [Abstract][Full Text] [Related]
19. EMA Recommendation for the Pediatric Indications of Plerixafor (Mozobil) to Enhance Mobilization of Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Children with Lymphoma or Malignant Solid Tumors.
Karres D; Ali S; van Hennik PB; Straus S; Josephson F; Thole G; Glerum PJ; Herberts C; Babae N; Herold R; Papadouli I; Pignatti F
Oncologist; 2020 Jun; 25(6):e976-e981. PubMed ID: 32154610
[TBL] [Abstract][Full Text] [Related]
20. Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor.
Uchida N; Leonard A; Stroncek D; Panch SR; West K; Molloy E; Hughes TE; Hauffe S; Taylor T; Fitzhugh C; Hankins JS; Wilson M; Sharma A; Tsai SQ; Weiss MJ; Hsieh M; Tisdale JF
Haematologica; 2020 Oct; 105(10):e497. PubMed ID: 33054091
[No Abstract] [Full Text] [Related]
[Next] [New Search]
